Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) Short Interest Update

Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) was the recipient of a significant growth in short interest in April. As of April 30th, there was short interest totaling 821,485 shares, a growth of 120.0% from the April 15th total of 373,385 shares. Approximately 17.4% of the shares of the company are sold short. Based on an average daily volume of 52,694,940 shares, the short-interest ratio is currently 0.0 days.

Wall Street Analysts Forecast Growth

ASBP has been the subject of several analyst reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Aspire Biopharma in a report on Monday, April 20th. Wall Street Zen raised shares of Aspire Biopharma to a “sell” rating in a report on Saturday, January 17th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has an average rating of “Sell”.

Aspire Biopharma Stock Down 4.4%

NASDAQ ASBP opened at $5.61 on Friday. The stock has a market capitalization of $936,870.00, a P/E ratio of -0.28 and a beta of 0.21. Aspire Biopharma has a 52-week low of $3.31 and a 52-week high of $1,050.36. The firm has a 50-day moving average price of $20.67 and a 200 day moving average price of $90.13.

Aspire Biopharma (NASDAQ:ASBP) last posted its quarterly earnings results on Friday, May 15th. The company reported ($20.57) earnings per share (EPS) for the quarter. The company had revenue of $0.03 million for the quarter.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. XTX Topco Ltd increased its holdings in Aspire Biopharma by 853.2% in the fourth quarter. XTX Topco Ltd now owns 265,471 shares of the company’s stock valued at $35,000 after buying an additional 237,620 shares in the last quarter. Jane Street Group LLC increased its holdings in Aspire Biopharma by 2,252.1% in the fourth quarter. Jane Street Group LLC now owns 688,143 shares of the company’s stock valued at $91,000 after buying an additional 658,886 shares in the last quarter. Finally, CIBC Bancorp USA Inc. purchased a new position in Aspire Biopharma in the third quarter valued at about $28,000. 19.17% of the stock is owned by hedge funds and other institutional investors.

Aspire Biopharma Company Profile

Aspire Biopharma Inc is a specialty pharmaceutical company dedicated to developing and commercializing inhaled therapeutics for cardiopulmonary emergencies and respiratory diseases. The firm leverages proprietary formulation and drug-delivery technologies to repurpose established active pharmaceutical ingredients, aiming to enhance onset of action and improve patient convenience in acute settings. Aspire’s focus on pulmonary administration differentiates its approach from traditional oral or injectable treatments for asthma, allergic reactions, and other respiratory conditions.

The company’s lead asset is a reformulated metered-dose inhaler version of epinephrine designed to serve as an over-the-counter or prescription rescue therapy for acute bronchospasm and anaphylaxis.